BJP MLA's 2 kin die of snakebite in Palamu
The victims are extended family members of BJP's incumbent Daltonganj MLA Alok Kumar Chourasia. Arjun Kumar (8) and his elder brother Deva (10) were bitten in their sleep at their home in Pathra village along with their father Prem. Bheem Chaurasia, the grandfather of the kids, said the trio were sleeping together. "They also set up a mosquito net. However, none of us know how the snake sneaked inside it," Bheem said.
Reacting to it, BJP MLA Alok Chourasia said, "I was on way to Delhi last night when it occurred. The victims are my kin. Prem is doing fine now."
All the three were taken to the MMCH for treatment. Palamu civil surgeon Dr Anil Kumar Srivastav said on duty doctors had administered polyvalent anti-venom injections. While the two children died at the hospital, Prem responded to the treatment and was then moved to a private hospital at Tumbagara, nearly 30 km away, on the family's request.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Enhance Online Presence and Get Customers [Try Now]
tocsinmag.com/aboutus
Undo
Family sources said the snake was spotted but it slithered down before being caught or killed.
A doctor of the MMCH said, "The snake must have bitten the children first. When it bit the man, the quantity of the venom must have lessened."
Additional collector Kundan Kumar said the victim's kin would be entitled to Rs 4 lakh compensation each.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
26 minutes ago
- Time of India
Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's weight loss pill doesn't appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. The result falls on the lower end of Wall Street's expectations. Shares of the company fell around 13% on Thursday, according to CNBC. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Thursday. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Eli Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat diabetes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Web Search search Search Now Undo Lilly says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of day. ALSO READ: Firefly Aerospace ignites Wall Street as it raises $868 million in biggest space IPO. All about SpaceX rival Live Events Eli Lily on daily GLP-1 pills Eli Lilly announced that its new orforglipron pill led to an average weight loss of up to 27.3 pounds, based on results from the first of two Phase 3 trials involving over 3,100 overweight or obese adults. "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." ALSO READ: VA terminates major union contracts and it will impact over 400,000 federal workers. What's at stake for you? Investors had high hopes that Lilly's pill, orforglipron, would match the effectiveness of Novo Nordisk's blockbuster weight-loss injection, Wegovy. In key trials, Wegovy helped users lose around 14% to 15% of their body weight — slightly below the weight loss seen with Lilly's competing shot, Zepbound. 'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.' Eli Lilly said that all adults participating in its Phase 3 trials experienced weight loss while taking orforglipron. Participants on the highest dose—36 mg—lost an average of 27 pounds over 72 weeks, equating to about 12% of their body weight. While this result is significant, it falls slightly short of the weight loss typically seen with some injectable treatments with the drugmaker noticing that about 10% of participants on the highest dose chose to discontinue the pill. ALSO READ: $1,702 stimulus check in August: Last chance to apply for PDF closes soon. Check key dates, eligibility, tax implication Beyond weight loss, trial participants saw improvements in cardiovascular markers, including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. Negative side effects were similar in frequency and nature to those observed with injectable GLP-1 medications. The most commonly reported side effects were mild to moderate gastrointestinal issues such as nausea, constipation, indigestion, diarrhea, and vomiting. Eli Lilly is also evaluating orforglipron's effectiveness in adults with Type 2 diabetes. In April, the company shared that the pill may help lower hemoglobin A1C levels—a key indicator of average blood sugar over two to three months—while also supporting weight loss. Eli Lilly aims to seek global regulatory approval for its daily oral orforglipron pill by the end of 2025, positioning itself alongside rival Novo Nordisk, which is pursuing approval for an oral form of its Wegovy (semaglutide) treatment. However, federal health regulators are expected to require more comprehensive data on the drug's safety, tolerability, and effectiveness before moving forward with any potential approval.
Time of India
an hour ago
- Time of India
Study reveals eating French fries can increase the risk of Type 2 diabetes by a shocking percentage
Image credits: Getty Images If French fries have been your go-to order at restaurants and a favoured side dish with meals, then it might be time to cut them out of your life. According to a new study published in The BMJ on August 6, 2025, the potato-based dish can elevate the risk of Type 2 diabetes by 20%. But, if you swap these out for whole-grain foods, these odds could decrease by 19%, according to the same study. The study focused on data involving more than 205,000 people enrolled in the Nurses' Health Study, the Nurses' Health Study II and the Health Professionals Follow-up Study. The participants filled out detailed dietary questionnaires for a long period for three decades, which included questions about how many times a week they ate French fries, whether they baked, boiled or mashed potatoes and how many times they ate whole grains in a week. Their health was also tracked to gain results, and over the period, a shocking 22,299 participants developed Type 2 diabetes. 'The public health message here is simple and powerful: Small changes in our daily diet can have an important impact on the risk of type 2 diabetes. Limiting potatoes — especially limiting French fries — and choosing healthy, whole grain sources of carbohydrate could help lower the risk of type 2 diabetes across the population,' said Dr Walter Willett, study co-author and professor of epidemiology and nutrition at Harvard University. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Kate Middleton's Daring Outfit Took Prince William's Breath Away Crowdy Fan Undo Who is to blame: French fries or potatoes? Image credits: Getty Images However, is it the fries or the vegetable itself? 'We're shifting the conversation from, 'Are potatoes good or bad?' to a more nuanced — and useful — question: How are they prepared, and what might we eat instead?' said Seyed Mohammad Mousavi, a postdoctoral research fellow in Harvard's Department of Nutrition and lead author of the study. It does matter how the potatoes are cooked. While just three servings a week of French fries elevated the diabetes risk by 20%, eating the vegetable as baked, boiled or mashed had absolutely no influence on the risk of the disease. Whole grains for the rescue Image credits: Getty Images Replacing the French fries order with whole grains, such as whole grain pastas or bread, reduced the risk of the disease by up to 19%. Even substituting whole grains with refined ones can add to the lowered diabetes risk. These findings were substantiated by 2 separate analyses where data from numerous previous studies involving more than 500,000 people led to similar results when it came to the battle of French fries versus whole grains. 'For policymakers, our findings highlight the need to move beyond broad food categories and pay closer attention to how foods are prepared and what they're replacing," Willett said in a Harvard news release. "Not all carbs — or even all potatoes — are created equal, and that distinction is crucial when it comes to shaping effective dietary guidelines.'
Business Standard
an hour ago
- Business Standard
Artemis Medicare Services Ltd Reports Robust Q1 FY26 Results with 28.2% Growth in Net Profit
VMPL Gurugram (Haryana) [India], August 7: Artemis Medicare Services Ltd. has announced robust performance for Q1 for financial year 2025-26, with a consolidated gross revenue of ₹2,681 million for Q1, an upturn of 14.4% year on year. The Board of Directors were pleased to have approved the financial results for the quarter ended June 30, 2025, showing steady performance on all metrics. The company's net revenue from operations went up by 14.2% to ₹2,550 million from ₹2,232 million in the first quarter of FY25. The company's EBITDA went up 19.0% to ₹483 million, with a good margin of 19.0%. Most importantly, net profit jumped 28.2% to ₹212 million, up from ₹165 million in the same quarter last year. Quarterly Artemis Hospital Gurgaon Performance Highlights Q1 FY2025-26 (Apr-Jun) vs Q1 FY2024-25 * Average gross revenue per occupied bed (ARPOB) was at Rs 83,900, as against Rs 79,200 * Net Revenue from operations was up 16.0% to close at Rs 2,412 Million, as against Rs 2,080 Million in Q1 FY25 * EBITDA reported was Rs 495 Million at a margin of 20.5%, as against Rs 415 Million * Bed capacity utilisation stood at 61.2% * Revenues from overseas patients increased by 31.4% to Rs 704 Million from Rs 536 Million * Overseas patients contributed 29% to Net Revenue * Average length of stay (ALOS) at 3.7 days compared to 3.6 days Quarterly Consolidated Performance Highlights Q1 FY2025-26 (Apr-Jun) vs Q1 FY2024-25 * Net Revenue from operations was up 14.2% to close at Rs 2,550 Million, as against Rs 2,232 Million in Q1 FY25 * EBITDA reported was Rs 483 Million at a margin of 19.0%, as against Rs 406 Million * Net profit for Q1 closed at Rs 212 Million, as against Rs 165 Million in the Q1 FY25 Artemis Hospital in Gurgaon also delivered impressive results. The hospital's net income went up 16.0% to ₹2,412 million. The average revenue per occupied bed (ARPOB) went up to ₹83,900, the highest it has ever been. In Q1 FY25, it was ₹79,200. EBITDA for the hospital went up to ₹495 million, keeping a margin of 20.5%. Overseas sales were a big part of this, going up by 31.4% to ₹704 million, which is 29% of net sales. The average length of stay (ALOS) was 3.7 days, and 61.2% of the beds were full. Commenting on the company's performance, Onkar Kanwar, Chairman, Artemis Medicare Services Ltd said "We are pleased to announce a strong start to FY26, with Q1 delivering consistent growth and resilient operational performance despite being a seasonally soft quarter. Our continued focus on cost optimization, operational efficiency, and disciplined execution has enabled us to maintain healthy profitability and margins. Our highest-ever ARPOB, driven by an optimized case and payer mix and strong international patient inflow, reinforces our position as a leader in Medical Value Travel. During the quarter, we added new beds at our flagship hospital's third tower, strengthening capacity and improving unit economics in the coming quarters. We also signed a binding MoU with Dr. Vidya Sagar Kaushalya Devi Memorial Health Centre for a proposed Medical Services Agreement, marking an important step in expanding in North India. On the clinical front, we launched India's first private Geriatrics & Longevity Department and partnered with KIMS, Hyderabad for heart-lung transplants, underscoring our commitment to advanced patient-centric care. Looking ahead, we remain focused on sustainable growth through operational excellence, geographic expansion and strategic partnerships, as we continue building Artemis into one of India's most trusted healthcare brands."
